N91115

DRUG4 trials

Sponsors

Nivalis Therapeutics, Inc.

Conditions

Cystic FibrosisDrug Interaction PotentiationHealthy

Phase 1

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

CompletedNCT02013388

Nivalis Therapeutics, Inc.Healthy

Start: 2014-02-28End: 2015-02-28Updated: 2016-12-21

PK Study of N91115 in Cystic Fibrosis Patients

CompletedNCT02227888

Nivalis Therapeutics, Inc.Cystic Fibrosis

Start: 2014-10-31End: 2015-01-31Updated: 2016-11-07

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

CompletedNCT02275936

Nivalis Therapeutics, Inc.Cystic Fibrosis

Start: 2015-02-28End: 2015-07-31Updated: 2016-11-07

A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

CompletedNCT02500667

Nivalis Therapeutics, Inc.Drug Interaction Potentiation

Start: 2015-06-30End: 2015-08-31Updated: 2016-11-07

Related Papers

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

2017-02-1337 citations